

February 15, 2007

AnGes MG, Inc.

Toyobo and GenomIdea Forms Business Alliance
- Product Launch of Master Cell Bank for Drug Manufacturing -

AnGes MG, Inc. announces that GenomIdea, Inc., its subsidiary, concluded a distributorship agreement with Toyobo, Co., Ltd. for the master cell bank developed and under patent application by GenomIdea. The cell bank is expected to be available in the market in March 2007.

The master cell bank invented by GenomIdea is cell lines that are cultured and proliferated with specific conditions based on the regulatory authority's guidelines and subdivided in numerous containers to be used for manufacturing of biological drugs. Quality tests on pathogen contamination have been performed for the master cell bank in accordance with the guidelines so that it can be adopted for drug manufacturing. It has characteristics where cells can be proliferated in culture media not containing bovine serum for the prevention of bovine spongiform encephalopathy (BSE) pathogen, and prepared from suspended cells to be suitable for scale-up in culture tanks.

Unlike the conventional master cell banks requiring an extremely high cost for preparation, the master cell bank will be released at a more affordable price in collaboration with Toyobo. We believe this cost-effectiveness will contribute to the nurturing of Japanese biological companies.

By executing this agreement, Toyobo will begin marketing the master cell bank in March 2007, and in return, GenomIdea will receive part of its sales as royalties.

This master cell bank was developed as part of the "Fundamental Technology Research Facilitation Program (Private Sector Fundamental Technology Research Support Scheme)" adopted by the New Energy and Industrial Technology Development Organization (NEDO) in 2002.